Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study

Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study

Abstract Rivaroxaban, a direct oral anticoagulant, is effective against venous thromboembolism (VTE) recurrence without increasing the risk of major bleeding in patients with cancer-associated venous thromboembolism (CAT). However, its clot regression effects are poorly understood. This single-arm,...

Full description

Bibliographic Details
Main Authors: Shigeki Takai, Naohiko Nakanishi, Isao Yokota, Kojiro Imai, Ayumu Yamada, Takanori Kawasaki, Takeru Kasahara, Takashi Okada, Takahisa Sawada, Satoaki Matoba
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-26150-w

Internet

https://doi.org/10.1038/s41598-022-26150-w

Similar Items